SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East shipping and energy-infrastructure threats are driving crude-oil supply concerns and attention to USO. Traders are split between expecting further gains if disruptions persist and anticipating a pullback if diplomacy or additional supply eases the risks; many also worry that elevated oil prices could pressure equities and inflation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure after HSBC warned that heavy borrowing needs and potentially slower AI-compute demand could challenge its growth and returns, sharpening traders concerns about debt, refinancing, and dilution amid a broader neocloud selloff. Bears warn of credit and business-model risks, while bulls point to contracted demand and continued AI infrastructure growth; some also cite Goldman Sachss more positive view and ARKs share purchases.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO slide and fresh lows are driving discussion, with traders pointing to continued lockup-related share supply and insider selling, as well as a TD Cowen price-target cut and concerns about growth and customer concentration. Bearish traders expect more pressure, while some bullish holders view the decline as an oversold buying opportunity and argue the companys AI-chip technology has long-term potential.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius has been caught in a sharp neocloud and AI-infrastructure selloff as traders debate whether heavy buildout spending can earn adequate returns and whether financing risksespecially at CoreWeavewill spread across the sector. The community is split between treating the rebound after the decline as an oversold bounce and expecting more downside, while some argue Nebius is better positioned than debt-heavier peers and that compute demand remains strong.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and limited firm customer commitments, with uncertainty around the proposed TVA deployment adding to execution concerns. Traders are split between viewing the selloff as an overreaction and seeing it as confirmation of risks facing NuScale and the broader nuclear sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent selloff, ahead of major megacap earnings, is driving QQQ discussion. Traders are divided over whether it marks a durable recovery or a relief rally that could fade, with AI investment and debt concerns and surging oil prices adding to caution.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces third-quarter earnings beat and raised 2026 guidance are driving attention, with traders also citing stronger orders. Many view the report as bullish, while others are cautious about whether the stock can hold its post-earnings strength amid muted or weakening price action.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat estimates, but traders are focused on the tightened full-year profit outlook rather than a larger guidance increase. The new buyback program is a positive offset for some, while others question why shares are falling despite the beat.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention ahead of its Q3 earnings report, with traders anticipating a beat and stronger guidance while citing major missile and counter-drone awards as signs of sustained defense demand. Optimism about a rebound competes with concerns that expectations are high and contract wins have not always translated into stronger share performance.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrops Q3 results beat expectations and management raised its full-year outlook, with a record backlog reinforcing the growth case. Traders are debating why shares remain under pressure despite the strong report, pointing to margin and cash-flow concerns and the possibility that the positive news was already priced in.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy

Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees

Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees...

3 Cancer Stocks to Watch as Oncology Innovation Accelerates

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Autolus Therapeutics Q1 Earnings Call Highlights

Autolus Therapeutics Q1 Earnings Call Highlights...

HC Wainwright Has Negative Outlook for AUTL Q2 Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Autolus Therapeutics in a note issued to investors on Thursday, April 30th. HC Wainwright analyst E. Bodnar now anticipates that the company wil...

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the company...

Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Jefferies Financial Group

Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday...

Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround

Autolus Therapeutics (NASDAQ:AUTL) is seeking to differentiate itself in the CAR-T market by pairing strong clinical activity with a safety profile that could allow broader patient access, CEO...

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc - ADR

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Aucatzyl will be available through routine commissioning by the NHS, the company said.</li><li>Aucatzyl was approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024.</li><li>The company also intends to launch Aucatzyl in England and Wales soon, It added.</li></ul> Autolus Therapeutics Plc (AUTL) said on Tuesday that the UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending its Aucatzyl CAR T cell therapy for use in the National Health Service (NHS) in England and WalesShares of the company rose 14% in the premarket session at the time of writing.<h2 class="st-heading-2">UK Approval And Recommendation</h2>NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/nice-recommends-aucatzylr-obecabtagene-autoleucel-treatment">said</a>. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia is a cancer that either returns after treatment or never responded to initial therapy.Aucatzyl will be available through routine commissioning by the NHS, the company said. The company also intends to launch Aucatzyl in England and Wales soon, it added.Aucatzyl or obecabtagene autoleucel is an autologous CD19 CAR T cell therapy. Autologous CD19 CAR T-cell therapy is an immunotherapy that uses a patient's own T-cells, which are genetically modified to target and attack cells that express the CD19 protein. This treatment has shown high efficacy in relapsed or refractory B-cell malignancies.The U.S. Food and Drug Administration approved Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024. A conditional marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) followed in April 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AUTL stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘normal’ levels.A Stocktwits user sees the stock hitting as high as $2.50.<stembedurl>https://stocktwits.com/nader_1/message/637361441</stembedurl>Another applauded the recent announcement and expressed hope that cell therapy would become the standard of care.<stembedurl>https://stocktwits.com/janed102/message/637360741</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by 47% this year and by about 58% over the past 12 months. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-keys-stock-surge-14-in-premarket-today/cL52hzFREX8">Why Did KEYS Stock Surge 14% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Autolus Therapeutics Ltd - ADR

iShares Health Innovation Active ETF

Tema Oncology ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$1.59
Prev Close	$1.60
Open	$1.59
Dividend Yield	0.00%
50-Day Moving Average	$2.03
Beta	1.42
Avg. Volume	1.61M
PE Ratio	-1.51

52-Week High	$2.58
52-Week Low	$1.18
Market Capitalization	$423.2M
EPS (Annual)	-$1.08
Price to Book	7.54
Revenue Per Employee	$100,484.27

Feed

News

Sentiment

Earnings

Fundamentals

Info

AUTL Fundamentals